Hepatitis B News and Research

Latest Hepatitis B News and Research

Financial and political commitments to improve health of women and children

In only one year, more than 100 countries, foundations, multilateral organizations, the UN, the private sector, and academic and professional associations have made unprecedented financial and political commitments to greatly improve the health of women and children.

21 Sep 2011

Scientists discover how liver destroys immune T-cells

Scientists at the Centenary Institute in Sydney have seen for the first time (in mice) how the liver goes independent, engulfing and destroying the body's defence troops-T-cells.

20 Sep 2011

Chronic diseases could cost $47 trillion over the next 20 years: Report

A latest report by the World Economic Forum (WEF) suggests that the global economic impact of the five leading chronic diseases -- cancer, diabetes, mental illness, heart disease, and respiratory disease - could reach $47 trillion over the next 20 years.

19 Sep 2011

Georgia reminds adults to get vaccinated

Vaccines aren't just for kids, adults need protection too! September 18 kick starts National Adult Immunization Awareness Week and the Georgia Department of Public Health reminds Georgians that you never outgrow the need for vaccines.

16 Sep 2011

Teva to invest in CDI for development of novel antiviral drugs

Teva Pharmaceutical Industries Ltd. announced today that it has signed a collaboration option to license and share purchase agreements to invest in Cocrystal Discovery Inc. (CDI), a biopharmaceutical company focused on the discovery and development of novel antiviral therapeutics for the treatment of serious and chronic viral diseases.

16 Sep 2011

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

Treatment with a telaprevir-based combination regimen for hepatitis C - heretofore a chronic, destructive and difficult to manage disease - effectively can be shortened to six months in about two-thirds of patients, finds a new study published Thursday in the New England Journal of Medicine.

16 Sep 2011

Experimental malaria vaccine shows positive results among children in small Burkina Faso study

"An experimental malaria vaccine tested on children in Burkina Faso has shown 'a high level of efficacy' in protecting against the disease, a study published in" Thursday's New England Journal of Medicine said, according to Agence France-Presse.

16 Sep 2011

VBI Vaccines completes acquisition of Epixis

VBI Vaccines (VBI), a biotechnology company dedicated to the innovative formulation, development and delivery of safe and effective vaccines, announced today that it has completed the acquisition of Epixis S.A., a French biotechnology company developing its "eVLP" platform technology for a new generation of Virus-Like Particle (VLP) vaccines.

15 Sep 2011

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

University of Cincinnati research published in the Sept. 14, 2011, advance online edition of the New England Journal of Medicine shows that patients with hepatitis C who took a combination medication-a telaprevir-based regimen that is commonly used to treat the illness-for 24 weeks were cured.

15 Sep 2011

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

Vertex Pharmaceuticals Incorporated today announced that the New England Journal of Medicine (NEJM) published data from a Phase 3 study of INCIVEK (telaprevir) tablets in people with genotype 1 chronic hepatitis C who were new to treatment.

15 Sep 2011

'Achilles' heels' within HCV virus

Hopes for an effective vaccine and treatment against the potentially fatal hepatitis C virus (HCV) have received a major boost following the discovery of two 'Achilles' heels' within the virus.

14 Sep 2011

Breakthrough opens new avenues for hep C vaccine

Hopes for an effective vaccine and treatment against the potentially fatal hepatitis C virus (HCV) have received a major boost following the discovery of two ‘Achilles’ heels’ within the virus.

12 Sep 2011

Specialists propose changes to allocation and distribution of organs for liver transplants

Transplantation specialists have proposed changes to the allocation and distribution of organs used for liver transplants. The recommended policy modifications take into account the scarcity of available organs, ensuring rapid allocation and delivery of the organ to those most in need in order to reduce mortality for waitlisted patients.

12 Sep 2011

HPV vaccination updates

Texas Governor Rick Perry's GOP rivals sharply criticized him during Wednesday night's debate over his 2007 executive order mandating that teenage girls be vaccinated to prevent cervical cancer. The move had drawn strong opposition at the time from social conservatives and was later overturned by the state Legislature.

9 Sep 2011

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

Pharmasset, Inc., announced today sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 400 mg dosed once daily in combination with peginterferon alfa 2a and ribavirin (Peg-IFN/RBV) in subjects with hepatitis C virus (HCV) genotype 1 who have not been treated previously. 43 out of 44 (98%) evaluable subjects achieved an SVR12, defined as HCV RNA below the limit of detection (<15 IU/mL) 12 weeks after the completion of treatment.

6 Sep 2011

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Gilead Sciences, Inc. today announced that, in consultation with the U.S. Food and Drug Administration (FDA), the company will amend the design of ongoing clinical trials to discontinue dosing of GS 9190 in hepatitis C-infected patients who are receiving that compound in combination with pegylated interferon and ribavirin, and another direct-acting antiviral agent.

5 Sep 2011

Wis. patients getting tested for HIV after misuse of equipment

Milwaukee Journal Sentinel reports that a nurse misused equipment to teach diabetic patients how to inject insulin. Meanwhile, researchers look at how hospital uniforms can carry germs.

2 Sep 2011

Engineered virus shows promise in cancer therapy via bloodstream

Scientists have engineered a virus that when injected into the blood, can selectively target cancer cells throughout the body. The virus attacked only tumours, leaving the healthy tissue alone, in a small trial on 23 patients, according to the journal Nature.

2 Sep 2011

Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection

MedivirAB is an emerging researchbased specialty pharmaceutical company focused on infectious diseases. Medivir today announced that its investigational protease inhibitor TMC435, developed by Tibotec Pharmaceuticals, has successfully completed enrollment of three ongoing global phase 3 trials and further reports that all patients are now on TMC435 or active control treatment.

31 Aug 2011

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Medivir: Interim period (January 2011 - June 2011). Net sales were SEK 444.6 (35.7) m.

31 Aug 2011

Hepatitis B News and Research

Latest Hepatitis B News and Research

Financial and political commitments to improve health of women and children

Scientists discover how liver destroys immune T-cells

Chronic diseases could cost $47 trillion over the next 20 years: Report

Georgia reminds adults to get vaccinated

Teva to invest in CDI for development of novel antiviral drugs

Shorter treatment with telaprevir-based combination regimen may benefit hepatitis C patients

Experimental malaria vaccine shows positive results among children in small Burkina Faso study

VBI Vaccines completes acquisition of Epixis

Patients with hepatitis C may benefit from 24 week telaprevir-based regimen

NEJM publishes data from Vertex INCIVEK Phase 3 study on genotype 1 chronic hepatitis C

'Achilles' heels' within HCV virus

Breakthrough opens new avenues for hep C vaccine

Specialists propose changes to allocation and distribution of organs for liver transplants

HPV vaccination updates

Pharmasset reports SVR results from PSI-7977 phase 2b combination study on HCV genotype 1

Gilead to amend design of ongoing clinical trials against chronic hepatitis C

Wis. patients getting tested for HIV after misuse of equipment

Engineered virus shows promise in cancer therapy via bloodstream

Medivir completes enrollment of three TMC435 phase 3 trials on CHC genotype-1 infection

Medivir reports net sales of SEK 444.6 m for 1 January - 30 June 2011

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Hepatitis B News and Research

Latest Hepatitis B News and Research

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Exploring electron microscopy for plant and microbial imaging at the John Innes Centre

Newsletters you may be interested in